<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6143">
  <stage>Registered</stage>
  <submitdate>8/07/2016</submitdate>
  <approvaldate>8/07/2016</approvaldate>
  <nctid>NCT02843659</nctid>
  <trial_identification>
    <studytitle>Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome</studytitle>
    <scientifictitle>A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjögren's Syndrome</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2016-000101-37</secondaryid>
    <secondaryid>IM128-035</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Sjögren's Syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Autoimmune diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BMS-931699
Treatment: drugs - BMS-986142
Treatment: drugs - Placebo

Experimental: BMS-931699 - Subcutaneous weekly injection + daily oral placebo tablets

Experimental: BMS-986142 - Daily oral tablets + subcutaneous placebo (weekly) injection

Placebo Comparator: Placebo - Weekly subcutaneous placebo injection +daily oral placebo tablets


Treatment: drugs: BMS-931699
Specified dose on specified days

Treatment: drugs: BMS-986142
Specified dose on specified days

Treatment: drugs: Placebo
Specified dose on specified days

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from baseline in EULAR SS Disease Activity Index (ESSDAI) score at Week 12 - Changes will be compared between active treatment arms (lulizumab or BMS-986142, respectively) and the placebo arm.</outcome>
      <timepoint>From Day 1 and Week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in EULAR SS Patient-Related Index (ESSPRI) score at Week 12</outcome>
      <timepoint>From Day 1 and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with = 3 points of improvement from baseline in ESSDAI at Week 12</outcome>
      <timepoint>Day 1 to Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with = 1 point of improvement from baseline in ESSPRI at Week 12</outcome>
      <timepoint>Day 1 to Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with both = 3 points improvement in ESSDAI and = 1 point improvement in ESSPRI from baseline at Week 12</outcome>
      <timepoint>Day 1 to Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in ESSDAI scores at Week 4 and Week 8</outcome>
      <timepoint>Up to 8 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in ESSPRI scores at Week 4 and Week 8</outcome>
      <timepoint>Up to 8 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in ESSPRI individual component dryness score at Weeks 4, 8, and 12</outcome>
      <timepoint>Up to 12 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in ESSPRI individual component fatigue score at Weeks 4, 8, and 12</outcome>
      <timepoint>Up to 12 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in ESSPRI individual component pain score at Weeks 4, 8, and 12</outcome>
      <timepoint>Up to 12 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in unstimulated salivary flow rate at Weeks 4, 8, and 12</outcome>
      <timepoint>Up to 12 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in stimulated salivary flow rate at Weeks 4, 8, and 12</outcome>
      <timepoint>Up to 12 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in ocular surface staining test at Weeks 4, 8, and 12</outcome>
      <timepoint>Up to 12 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in Schirmer's test at Weeks 4, 8, and 12</outcome>
      <timepoint>Up to 12 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in the tear break-up time test at Weeks 4, 8, and 12</outcome>
      <timepoint>Up to 12 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of all Adverse Events (AEs), Serious Adverse Events (SAEs), and any pre-established Events of Special Interest for lulizumab</outcome>
      <timepoint>Up to 18 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of clinically significant abnormalities in general laboratory tests for lulizumab</outcome>
      <timepoint>Up to 18 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of clinically significant ECG abnormalities for lulizumab</outcome>
      <timepoint>Up to 12 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of clinically significant abnormalities in vital signs for lulizumab</outcome>
      <timepoint>Up to 18 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of all Adverse Events (AEs), Serious Adverse Events (SAEs), and any pre-established Events of Special Interest for BMS-986142</outcome>
      <timepoint>Up to 18 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of clinically significant abnormalities in general laboratory tests for BMS-986142</outcome>
      <timepoint>Up to 18 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of clinically significant ECG abnormalities for BMS-986142</outcome>
      <timepoint>Up to 12 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of clinically significant abnormalities in vital signs for BMS-986142</outcome>
      <timepoint>Up to 18 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Numeric rating scale (NRS) for mouth dryness</outcome>
      <timepoint>Day 1 to Week 18</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Numeric rating scale (NRS) for eye dryness</outcome>
      <timepoint>Day 1 to Week 18</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Numeric rating scale (NRS) for vaginal dryness</outcome>
      <timepoint>Day 1 to Week 18</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Subject Global Assessment of Disease activity</outcome>
      <timepoint>Day 1 to Week 18</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Physician Global Assessment of Disease activity</outcome>
      <timepoint>Day 1 to Week 18</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Short Form-36 acute (SF-36 acute)</outcome>
      <timepoint>Day 1 to Week 18</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Female Sexual Function Index (FSFI)</outcome>
      <timepoint>Day 1 to Week 18</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Work Participation and Activity Impairment Questionnaire (WPAI)</outcome>
      <timepoint>Day 1 to Week 18</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient Reported Outcomes Measurement Information System Fatigue Short Form (PROMIS Fatigue Short Form)</outcome>
      <timepoint>Day 1 to Week 18</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Trough concentrations of lulizumab and BMS-986142 in pSS subjects</outcome>
      <timepoint>Day 1 to Week 18</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        

          -  Subjects diagnosed or classified as having moderate to severe primary Sjögren's
             Syndrome based on the 2016 ACR-EULAR Sjögren's Syndrome Classification Criteria for at
             least 16 weeks prior to screening

          -  ESSDAI = 5 including disease activity (any score &gt; 0) in at least one of the following
             domains: Glandular, Articular, Hematological, Biological, Lymphadenopathy

          -  Positive anti-SS-A/Ro and/or anti-SS-B/La autoantibody

          -  Unstimulated whole saliva secretion &gt; 0.01 ml/min

          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
             test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to
             the start of study drug and must not be pregnant or breastfeeding. Male and female
             subjects must be willing to adhere to protocol-mandated highly effective contraception
             for the duration of the study and for the protocol-specified follow up period.
             Hormone-based contraceptive methods are not permitted</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Secondary Sjögren's syndrome or the presence of any other systemic autoimmune disease
             (eg, RA, SLE, multiple sclerosis, vasculitis)

          -  Very severe primary Sjögren's syndrome or severe complications of primary Sjögren's
             syndrome at the time of the screening visit

          -  Active systemic or latent bacterial (including tuberculosis), viral or fungal
             infection, evidence of current or chronic Hepatitis B or C infection, or HIV infection

          -  Any significant concurrent medical condition at the time of screening or baseline
             visit

          -  Use of methotrexate, cyclophosphamide, cyclosporine, tacrolimus, azathioprine,
             mycophenolate mofetil (MMF) or leflunomide within 12 weeks of screening visit

          -  Previous treatment with biologics therapies either marketed or in development within 6
             months prior to screening visit

          -  Treatment started or an unstable dose of hydroxychloroquine within 8 weeks of
             screening visit

          -  Oral corticosteroids &gt; 10 mg/day within 14 days of dosing (Day 1), corticosteroid
             therapy = 1 mg/kg during the 4 weeks preceding enrollment, or intravenous,
             intramuscular or intra-articular corticosteroids within 4 weeks of screening visit

        Other protocol defined inclusion/exclusion criteria could apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>18/10/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>24/07/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Local Institution - Camperdown</hospital>
    <postcode>2050 - Camperdown</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Metropolitana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Cundinamarca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Bogota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Cali</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pisa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Distrito Fededral</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Jalisco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Yucatan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Veracruz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>Lima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>San Juan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Western Cape</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of this study is to evaluate the efficacy of treatment with either
      lulizumab or BMS-986142 versus placebo in subjects with moderate to severe primary Sjögren's
      syndrome as measured by the change from baseline in ESSDAI at Week 12 between active
      treatment arms (lulizumab or BMS-986142, respectively) and the placebo arm.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02843659</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>